| Similar Articles |
|---|
 |
Pharmaceutical Executive
December 1, 2010
William Looney |
In Through the Out Door The end of anther year is an appropriate time to highlight the march of time and the transitions that accompany it in Europe and in China.   |
Pharmaceutical Executive
December 1, 2011
William Looney |
2011: End of the Beginning The gap in perception is one of industry's biggest problems because it adds ballast to the idea that medicines are just a simple procurement item. |
Pharmaceutical Executive
January 21, 2014
William Looney |
For Russia -- Tough Love Pharm Exec begins its 34th year with a feature on Russia's ambitious plans to build a homegrown biopharma business. Back in 1980, the biotech industry did not exist. |
Pharmaceutical Executive
June 9, 2014
Kleinrock & Noor |
Pharm Exec's Pharma 50 2014 For those companies in this year's Pharm Exec Top 50, meeting the accelerating market demand for specialty products has become an acute strategic imperative. |
Pharmaceutical Executive
May 1, 2011
William Looney |
Keeping Your Place on the Nifty 50 What do the Pharm Exec 50 numbers tell us? The dominant theme seems to be one of gradual restructuring toward a post-patent-cliff era. |
Pharmaceutical Executive
September 1, 2013
William Looney |
High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets. |
Pharmaceutical Executive
August 1, 2011
William Looney |
Innovation at Pfizer A Q and A with Kristin Peck, the drug maker's Executive Vice President, Worldwide Business Development and Innovation. |
Pharmaceutical Executive
June 1, 2012
William Looney |
From the Editor:The Connections Game As the old Broadway song goes, June is busting out all over, and true to the season this month's issue stretches the seams with content that ranges from the sublime to the ridiculous. |
Pharmaceutical Executive
January 21, 2014
Tim Powell |
Innovation: The Moneyball Test Successful innovation now has to align with key metrics of value; can an old baseball metaphor help guide the way? |
Pharmaceutical Executive
January 1, 2012
William Looney |
Pharma 2012: Hard Times Before the Harvest 2012 will be a transition year for pharma, one of the most important in its history. The challenge is that many new treatments may not complete the move from 'bench to bedside' in time to plug the yawning revenue gap. |
Pharmaceutical Executive
February 1, 2011
William Looney |
To Align an Audience, Find a Pulse All this uncertainty at the back end of drug development is a drain on future therapeutic progress against disease. It's a job killer, too. |
Pharmaceutical Executive
September 1, 2010 |
Looking Beyond the Patent Cliff Pfizer's VP and Assistant General Counsel for Global Patents and Policy, Roy Waldron, discusses its collaborative strategy to refresh the face of IP. |
Pharmaceutical Executive
September 1, 2005
Parker & Amar |
Building Blockbusters The most lucrative new drugs are often less glamorous than first-in-class new molecular entities. And they are much less risky. |
Pharmaceutical Executive
April 1, 2011 |
The Big Business of Boosting Performance Dutch-based DSM N.V. is seeking innovative ways to partner through bolstering manufacturing. |
Pharmaceutical Executive
July 1, 2011
William Looney |
Truth Found in the Wrong Places More bad ideas on how to manage the healthcare burden are circulating beyond the stakeholders that initiated them. |
The Motley Fool
April 19, 2006
Brian Gorman |
Pfizer Inches Forward The pharma continues on cost-cutting and gives back to shareholders, but R&D productivity remains a tough challenge. |
Pharmaceutical Executive
August 1, 2011
Ben Comer |
Is the 'Emerging Market' a Dated Concept? When it comes to the emerging markets, executing a few key elements of success are more important than ever. |
Pharmaceutical Executive
January 1, 2011 |
The San Diego Story San DIego works as a locus for risky investments in the big ideas that lead to biotech breakthroughs |
Chemistry World
May 21, 2009
Matt Wilkinson |
Big Pharma set for generics boost Pharmaceutical firms have been rushing to ensure they minimize their losses by expanding their generics businesses and reach into emerging markets. |
Pharmaceutical Executive
December 1, 2008
Patrick Clinton |
Reason to Believe Here are a few things to be optimistic about in the pharmaceutical industry. |
Pharmaceutical Executive
September 1, 2010 |
Pharm Exec's Ninth Annual Industry Audit Professor Bill Trombetta takes a snapshot of the "Glamour 24" companies shaping the pharma industry this year and beyond. |
Pharmaceutical Executive
May 1, 2012 |
Value-Based Pricing: Too High a Price for UK Pharma? Changes to the system in the UK could finally put some real metrics behind the elusive concept of value but with payers clearly in the driver's seat, who needs clarity? |
Pharmaceutical Executive
January 1, 2013
Clark Herman |
Who Lost Syria? Thankfully, the civil war is not a public relations issue for Big Pharma, but the long-term business implications for the Middle East region are cagey. |
Pharmaceutical Executive
October 1, 2012
William Looney |
Bidding for the Stars and Stripes As the blockbuster sales model fades, the rush is on for a new formula for growth. "Good" growth: niched, balanced, and sustainable; with high margins from protected pricing; more patient-friendly than patent-centric; and where revenues draw from a deep reservoir of unmet medical need. |
Pharmaceutical Executive
May 1, 2014
William Looney |
What's Real in Deals Recent deal making signals that the rehabilitation of big Pharma has entered a new phase aligned around a new strategic thesis: specialization and value differentiation are preferable to sheer bulk. |
Pharmaceutical Executive
January 21, 2014
William Looney |
Russia's Bet on Biopharma Can innovation trump ideology? Russia faces a stark choice in betting on the visible hand of government in promoting a "world class" biopharmaceutical sector |
Pharmaceutical Executive
August 1, 2014
William Looney |
A Window on the Industry: The Emerging Pharma Leaders 2014 Pharm Exec's 2014 roster of emerging pharma leaders serves as a window on work in an industry that relies on human capital as the coinage of success. |
Pharmaceutical Executive
April 1, 2011 |
How US Health Reform Is Hitting Canada Canada's Russell Williams, of Rx&D, talks about the impact of US health reform on his role as chief spokesman for the country's R&D industry. |
BusinessWeek
October 18, 2004
Catherine Arnst |
The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma |
Pharmaceutical Executive
April 1, 2014
William Looney |
The Trials of Commerce Four commercial line executives serve as our jury of peers on what's in store for the future of pharma, and discuss the changing criteria for market success, from drugs to consumer products to vaccines. |
Pharmaceutical Executive
December 1, 2010 |
The Sum of All His Parts: Career Reflections of Europe's Chief Drug Regulator The European Medicines Agency is a unique institution, pursuing a mandate shared with a complex web of national and regional groups, each able to place a distinctive imprint around the delicate task of certifying the safety and efficacy of new drugs. |
Pharmaceutical Executive
September 1, 2012
William Looney |
The Margin Call Autumn is a good time to present our annual post on how well the industry is doing in harvesting value for shareholders. Our diverse list of 24 companies, drawn from Big Pharma to the established biotechs, presents a similarly mixed picture on returns. |
Pharmaceutical Executive
August 1, 2006 |
Introduction: Pharm Exec at 25 A pharmaceuticals magazine celebrates its 25th anniversary. |
Pharmaceutical Executive
January 21, 2014
Comer & Upton |
Pharm Exec's Annual Industry Outlook 2014 For Big Pharma, the merits of strategic focus and operational discipline are more important than ever. It is time to be decisive; muddling through is so yesterday. |
Pharmaceutical Executive
September 1, 2005
Bill Trombetta |
2005 Industry Audit Who's really on top in the pharmaceutical industry? |
Pharmaceutical Executive
January 1, 2009
Patrick Clinton |
Getting Across The pharmaceutical industry is in pursuit of new goals. |
Pharmaceutical Executive
April 1, 2007
Bill Trombetta |
Stealth Pharmas Big Pharma is different from the thousands of biotechs, specialty pharmas, generics makers, and other companies that make up Stealth Pharma. Yes, they have more money. But in what other ways are they different? And can we learn anything from the way Stealth Pharma competes? |
The Motley Fool
December 31, 2010
Brian Orelli |
How the Other Half of Pharma Lives A dive into spec pharma. |
Pharmaceutical Executive
July 1, 2012
William Looney |
The Learning Curve In a wake up call to this year's Emerging Leaders a group of St. Joseph's Business School Health Management alumni say time has no limit on surprises; change for pharma is here and it's good. |
Pharmaceutical Executive
September 1, 2012
Stan Bernard |
The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model. |
Pharmaceutical Executive
January 1, 2006
Sarah Houlton |
Global Report: The UK's New Code of Conduct Pharma companies' relationships with doctors are being tightened in the United Kingdom, after a major overhaul of the Association of the British Pharmaceutical Industry's Code of Practice. |
Pharmaceutical Executive
February 1, 2012
William Looney |
Brand Success: It's Not Serendipity A new generation of products for inflammatory disease is coming forward, promising better promise and possibly a cure. |
The Motley Fool
March 24, 2009
Robert Steyer |
Drugmakers Diversify -- Again Merck and Pfizer choose businesses they once eschewed. |
Pharmaceutical Executive
November 1, 2013 |
Roundtable on Market Access Market Access is a window on what matters in the real world of soaring patient expectations and crimped payer budgets for innovation. |
Pharmaceutical Executive
November 1, 2013
William Looney |
Payers: Late for the Party? Pharm Exec's two key features this month illustrate the strategic contradiction facing today's industry. |
Pharmaceutical Executive
January 1, 2007
Glass & Poli |
Forecast 2007: Connecting the Dots How do execs rank the issues facing the pharmaceutical industry? And what are the links they see between them? A new study reveals the industry's mental map of today's challenges. |
Pharmaceutical Executive
June 1, 2014
O'Connor et al. |
Challenges to the Specialty Business Model New constraints require new solutions. Innovative, value-based pricing models will be critical to securing reimbursement and continued market access of high-price drugs. |
Pharmaceutical Executive
October 1, 2006
Rob Scott |
Thoughtleader: Life After Lipitor A conversation with a former Pfizer executive who "launched the world's best-selling drug." |
Pharmaceutical Executive
September 1, 2013
William Looney |
Trying to Control Pharma Costs? A key issue for biopharma marketers today is balancing cost and value factors around specialty biologic drugs, particularly those for cancer and other high profile, life altering diseases. |
Pharmaceutical Executive
February 1, 2006
Chandler & Chicco |
Public Relations: Damage Control Unless pharma defines a compelling story, and defends it vigorously in the consumer marketplace, others will enter that vacuum and tell the story for it -- in far less flattering ways |
